Search

Objective: To investigate the risks of attempted and completed suicide in women who experienced a stillbirth, miscarriage, or termination of pregnancy within 1 year postnatally and compare this risk with that in women who experienced a live birth.Design: A nested case-control study.Setting: Linking three nationwide population-based data sets in Taiwan: the National Health Insurance Research Database, the National Birth Registry and the National Death Registry.Sample: In all, 485 and 350 cases of attempted and completed suicide, respectively, were identified during 2001-11; for each case, ten controls were randomly selected and matched to the cases according to the age and year of delivery.Methods: Conditional logistic regression.Main Outcome Measures: Attempted and completed suicidal statuses were determined.Results: The rates of attempted suicide increased in the women who experienced fetal loss. The risk of completed suicide was higher in women who experienced a stillbirth [adjusted odds ratio (aOR) 5.2; 95% CI 1.77-15.32], miscarriage (aOR 3.81; 95% CI 2.81-5.15), or termination of pregnancy (aOR 3.12; 95% CI 1.77-5.5) than in those who had a live birth. Furthermore, the risk of attempted suicide was significantly higher in women who experienced a miscarriage (aOR 2.1; 95% CI 1.66-2.65) or termination of pregnancy (aOR 2.5; 95% CI 1.63-3.82). In addition to marital and educational statuses, psychological illness increased the risk of suicidal behaviour.Conclusions: The risk of suicide might increase in women who experience fetal loss within 1 year postnatally. Healthcare professionals and family members should enhance their sensitivity to care for possible mental distress, particularly for women who have experienced a stillbirth.Tweetable Abstract: Suicide risk increased in women who had a stillbirth, miscarriage, or termination of pregnancy within 1 year postnatally. [ABSTRACT FROM AUTHOR]

Chitosan microparticles (CMs) are of potential interest for controlled delivery of therapeutic agents to cells and tissues, especially to mucosal-epithelial surfaces in the body. CM incorporation efficiency and release kinetics for betamethasone (B), an epimeric synthetic glucocorticoid, were investigated. Evidence for mild but significant inflammatory reactions in rat lung exposed to high CM concentrations was observed. Inflammation in the rat lung was significantly decreased by inhalation of B-loaded CMs (BCMs). Decreases in bronchoalveolar lavage fluid protein, content of polymorphonuclear neutrophils, lactate dehydrogenase (LDH) activity, lung tissue myeloperoxidase (MPO) activity, and leukocyte inifitration were observed. For all biochemical parameters tested, CMs loaded with 1.0-1.2 mg/kg B decrease the inflammation by 1.63 ± 0.14 fold, to near air-inhalation control levels. Thus, the drug was efficiently delivered and active in the pulmonary tissues by this technique. [ABSTRACT FROM AUTHOR]

Insulin-loaded poly(lactide) (PLA) microparticles were successfully prepared by 6% w/v PLA in the organic phase, 10% w/v PVP and varied types of 5% w/v electrolytes in the continuous phase, by using a water-in.-oil-in-water emulsion/ solvent extraction technique. Addition of electrolytes such as NaCl, CaCl2 into the external phase significantly improved insulin entrapment efficiency compared to the case of no additives. NaCl was the most effective for obtaining high entrapment efficiency, with microparticle yield 81.2%, trapping efficiencies 49%, insulin-loading level 5.5% w/v and mean particle size 14.8 μm. The distribution of insulin on the PLA microparticles surface, outer layer and core were 8, 37 and 43%, respectively. The cumulative release of insulin had an upper limit of ∼24% of the insulin load at 24 days. A steady release rate was 0.5 μR insulin/mg microparticles/day of insulin release maintained for 24 days. Total protein-leaking amount was reduced after addition of electrolytes in the continuous aqueous phase. Rabbit glucose levels were evaluated after subcutaneous 20 mg insulin-loaded PLA microparticles or PL.A blank microparticles. Study results show that the insulin-loaded PLA microparticles significantly reduced the glucose level than PLA blank microparticles. The insulin-loaded PLA microparticles, physicochemical characterization data and the animal result obtained in this study may be relevant in optimizing the PLA microparticle formulation incorporation and delivery insulin carriers. [ABSTRACT FROM AUTHOR]

Microparticles containing 5-fluorouracil (5-FU) were prepared using poly(dllactide-co-glycolide) with an oil-in-oil emulsion/solvent extraction technique. Particle characteristics including size distribution, 5-FU loading efficiencies, in vitro release and degradation were investigated. The dispersed phase was composed of PLG dissolved in dichloromethane, and the continuous phase was paraffin oil containing lecithin. 5-FU was successfully entrapped in the microparticles with trapping efficiencies up to 76%, loading level 10% w/v, and particle size 3 µm. Release profiles of 5-FU loaded microparticles were determined to follow a first-order-time relationship. An optimized preparation of 5-FU microparticles was achieved and was capable of controlling the release of 5-FU over 21 days with an in vitro delivery rate of 0.4 µg 5-FU/mg particles/ day in the study. Preliminary animal studies indicated that the 5-FU loaded microparticles as an ocular delivery system showed no ocular toxicity and no significant inflammatory response in rabbits for 2 months. The 5-FU loaded microparticles approach, with PLG, might be a potential for the application of long-term delivery of hydrophilic drugs in the eye. [ABSTRACT FROM AUTHOR]